Background. Neurological decline during radio(chemo)therapy of the brain is often attributed to disease progression or side effects of radiotherapy. Diagnosis of opportunistic neurotropic infections such as cytomegalovirus (CMV) infections is uncommon, even though high-grade gliomas and some brain metastases are known to contain CMV particles. We prospectively examined the frequency of CMV encephalopathy during radiotherapy of the brain.
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Reactivations of cytomegalovirus (CMV) are most well known to occur in transplant patients, closely linked to the amount of corticosteroids administered. 1 However, there have been few reports of glioblastoma patients suffering reactivation of CMV during chemotherapy with temozolomide. 2 In addition, glioblastoma patients are suspected to have higher prevalence of positivity for anti-CMV immunoglobulin (Ig)G 3,4 compared with the healthy population. 5, 6 As of yet, there has been no proven connection between occurrence of CMV infection and glioblastoma. 5 The presence of CMV DNA in peripheral blood of glioblastoma patients is presently under discussion. While Mitchell et al 6 found detectable CMV DNA in the peripheral blood of 16/20 patients-drawn during resection-Lehrer et al 7 did not find any in a series of 14 patients.
CMV particles have been shown to exist in the tissue of a high number of high-grade gliomas 6, 8 and brain metastases, 9 but not in surrounding nontumorous tissue or benign brain tumors. 8, 10 In high-grade gliomas, immunoreactivity to immediate-early (IE)1 -72, a CMV-encoded antigen, has been detected in more than 90% of the specimens (Mitchell et 6 and 78% (28/36) 10 of the cases. In contrast, Taher et al 9 examined brain metastases of patients with primary breast (n ¼ 41) and colorectal cancer (n ¼ 37). They detected CMV proteins in 99% (77/78) of the metastases. They also detected CMV DNA in 92% (11/12) of the metastases from primary breast cancer and 80% (12/15) of the metastases from primary colorectal cancer.
Especially in the outer zone of high-grade gliomas there are many histopathological differences from the typical "core" histology of gliomas, 11 leading to the hypothesis that "surrounding low-grade tumor," as can often be found on MRI, might actually be surrounding CMV infection.
CMV encephalitis is difficult to diagnose, as the virus can cause local encephalitis, 12 leading to a multitude of neurological symptoms. The latter can also be observed in patients suffering from malignant brain tumors or brain metastases. Moreover, viral encephalitis is known to mimic the radiological appearance of glioblastoma and vice versa, making distinguishing the two even more difficult. 13 At our department, the clinical observations of patients showing unexpected neurological decline during RT of the brain led to the diagnosis of CMV-associated encephalitis-like syndromes in 5 cases in 2014. In order to determine the frequency of CMV (re)activation during and after radio(chemo)-therapy (R(C)T) of the neurocranium, the prospective observational GLIO-CMV-01 study was started on November 1, 2014.
Patients and Methods
The GLIO-CMV-01 study (ClinicalTrials ID: NCT02600065) is a prospective observational, hypothesis-generating single-center study at the Department of Radiation Oncology at the Universitä tsklinikum Erlangen, Germany. This trial was performed in accordance with the Declaration of Helsinki and the European Guidelines for Good Clinical Practice. Approval was obtained from the ethics committee. The authors designed and coordinated the trial, oversaw the study conduct and reporting, managed the database, and wrote all drafts of the manuscript. All authors vouch for the accuracy and completeness of the data, for the analyses reported, and for the fidelity of the study to the protocol.
Study Population
Patients eligible for enrollment had histologically proven high-grade gliomas (World Health Organization [WHO] grades III-IV) or brain metastases with either planned local (chemo)-radiation treatment of the neurocranium or whole-brain radiation treatment (WBRT), respectively. Other criteria for enrollment included age over 18, no previous radiation treatment of the brain, and eligibility for MRI. The complete inclusion and exclusion criteria are provided in Supplementary Table S1 . All patients provided written informed consent before inclusion in the study.
Study Procedures
MR images and blood samples were obtained before, halfway through, and at the end of RT. Blood and MRIs were also obtained 3 and 6 months after RT or routinely at any time that symptomatic neurological decline was observed. MRIs were screened for any indication of disease progression or increased intracranial pressure, such as empty sella turcica, transverse sinus stenosis, optic disc protrusion, flattening of the posterior globe or prominence of the perioptic nerve CSF spaces, 14 hydrocephalus, or signs of herniation. Peripheral blood was drawn within days of the MRI (days elapsed: 4.88+4.45) and was tested for anti-CMV IgM, anti-CMV IgG, and CMV DNA by the Institute of Clinical and Molecular Virology, Universitä tsklinikum Erlangen (certified according to DIN EN ISO 15189). Viremia was considered proven if quantitative PCR showed .250 copies/mL blood in nonclotted whole blood, as defined by the laboratory (for all procedures, see Supplementary Table S2 for used primers [online only]). There was no differentiation between ",250 copies/mL" and "undetected."
CMV-associated encephalopathy was considered proven clinically and hematologically if new or worsening neurological symptoms were diagnosed by the treating physician (severe fatigue, severely decreased cognitive function, speech impairment, somnolence, impaired motor functions) and new viremia or increase of viral load was detected in the blood. Other explanations for the neurological symptoms were excluded via MRI. In case of infection, patients were treated with intravenous ganciclovir (5 mg/kg body weight twice per day for 14 d) or valganciclovir (900 mg per day for 14 d), followed by valganciclovir 450 mg once a day for 4 -6 weeks, according to the routine clinical scheme.
The treatment plan of the underlying tumorous disease remained unchanged.
Study Design
As there were no previous data on the number of patients suffering from CMV encephalitis during irradiation of the brain, we estimated a study sample of 250 patients or 2 years, based on the number of patients with CMV-associated encephalopathy Goerig et al.: Frequent occurrence of CMV-encephalopathy during radiotherapy we had treated in 2014 prior to the study (unpublished data, accepted for publication April 21, 2016 in Strahlentherapie und Onkologie). We estimated the number of cases to range between 3% and 5%. Considering the number of patients with brain cancer treated at our department, we estimated the need for 250 patients to see between 7 and 13 cases of CMV-associated encephalopathy. The primary endpoint was the development of CMV-associated encephalopathy requiring treatment. An interim analysis was planned after 50 patients had completed RT (as outlined in the clinical ethics). As the high number and clinical relevance of CMV reactivation and encephalitis-like deterioration became apparent, we decided to publish the data of those 50 patients (10 mo and 15 d of recruiting); the study will continue to get more data on the prognosis.
Statistical Analysis
Mantel -Cox and Gehan-Breslow-Wilcoxon tests were used to compare survival curves. A Pearson test was used to perform a linear regression to determine relevant factors for CMV reactivation. Fisher's exact test at a 2-sided alpha level of P ¼ .05 was used to compare characteristics of the groups with and without CMV reactivation. A Mann -Whitney test was used to compare dexamethasone levels between the 2 groups. The statistical analysis was performed using GraphPad Prism 6.0.
Results

Patients
Between November 1, 2014 and September 15, 2015, fifty patients requiring local RT of the brain for high-grade gliomas (n ¼ 23) 15 or WBRT for brain metastases (n ¼ 27) 16 were enrolled in the GLIO-CMV-01 study. Eighty-eight patients had been screened, 38 met exclusion criteria (insufficient proficiency in the German language [n ¼ 4], missing eligibility for
, and 2 patients previously included in the study were excluded from analysis because of death prior to treatment.
(Chemo)radiation treatment of high-grade gliomas consisted of fractionated local irradiation (single dose: 1.99+0.28 Gy; cumulative dose: 58.70+4.77 Gy) plus/minus simultaneous temozolomide. 17 WBRT for brain metastases consisted of fractionated local irradiation (single dose: 2.70+0.46 Gy; cumulative dose: 35.74+3.79 Gy) plus/minus stereotactic boost and simultaneous chemotherapy.
In all patients, we determined the pretherapeutic status of anti-CMV IgG, anti-CMV IgM, and the number of virus copies in peripheral blood. Thirty-two of 50 patients were positive for anti-CMV IgG (64%) pretherapeutically and retained this status throughout the study. For 2 glioma patients, we demonstrated the presence of viral DNA (650 and 5800 copies/mL) prior to therapy with one of them also being positive for anti-CMV IgM and both developing encephalitis-like neurological symptoms during R(C)T associated with increase in viral load. Tables 1 and 2 summarize the clinicopathological characteristics of patients with cerebral metastases and high-grade gliomas, respectively.
Primary Endpoint
Fifteen of 50 patients (30%) developed CMV viremia during radio(chemo)therapy of the brain ( Fig. 1 and Supplementary  Fig. S1 [online only]) (7/23 high-grade gliomas, 8/27 cerebral metastases). All 15 had been positive for anti-CMV IgG pretherapeutically (15/32; 48%). Only 2 patients retained/developed positivity for anti-CMV IgM during viremia. No patient negative for anti-CMV IgG developed viremia, indicating the infection to be a reinfection/reactivation rather than a primary infection. Of the 15 patients developing primary viremia or increase in viral load, 13 showed associated sudden onset of neurological decline (13/15; 87%). The number of virus copies was not associated with the severity of the symptoms. Apart from 2 patients who refused antiviral treatment and became somnolent within 72 h, all patients received treatment (9 ganciclovir, 2 valganciclovir). Response to treatment was not associated with the substance used. Clinical improvement was reached in all treated patients within 48 h. The amount of improvement was not associated with the time between onset of symptoms and start of antiviral treatment. The time delay between symptoms and treatment for the 11 treated patients was 5.18+4.73 days. The cumulative dexamethasone doses within 14 days before antiviral treatment (160.4+90.16 mg) and those within 14 days after the first day of antiviral treatment (135.8+99.10 mg) did not significantly differ (P ¼ .57), making a potential effect of added dexamethasone unlikely.
Long-term observation (6 mo) revealed 2 patients with CMV disease during RT suffering recurrent viremia despite initial successful antiviral treatment with no detectable virus after treatment.
As patients negative for anti-CMV IgG prior to therapy had no risk of developing CMV-associated encephalopathy or even viremia, for further analysis we concentrated on the group at risk: patients positive for anti-CMV IgG.
Prognostic Parameters
The occurrence of CMV reactivation associated with encephalopathy was comparable between patients with high-grade gliomas (6/14; 43%) and cerebral metastases (7/18; 39%) (P ¼ 1.00). For prognostic parameters, see Table 3 . Age .65 was highly prognostically relevant for both patients with cerebral metastases and those with high grade-gliomas (both: odds ratio [OR] 12.00; 95% CI, 2.18-66.06, P ¼ .004; high-grade gliomas: OR 23.80; 95% CI, 0.89-634.00; P ¼ .04; cerebral metastases: OR 16.00; 95% CI, 1.13 -194.70; P ¼ .05), as well as the amount of dexamethasone administered. The intake of dexamethasone differed significantly between patients developing CMV-associated encephalopathy and those who were not (Fig. 2) in terms of cumulative intake within 4 weeks prior to RT, cumulative intake during RT, and intake per day during RT. This difference was especially significant for patients with highgrade gliomas.
While the cumulative intake .177.00 mg dexamethasone during RT (OR 12.00; 95% CI, 218 -66.06; P ¼ .004) or intake Goerig et There is no statistically significant difference between the characteristics of whole group (middle column) compared with only those positive for anti-CMV IgG prior to therapy (right column). 
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In the high-grade glioma group, the amount of dexamethasone administered during RT remained associated with an increased risk for CMV reactivation and neurological symptoms (OR 14.00; 95% CI, 0.94 -207.70; P ¼ .09 for cumulative dexamethasone and OR 15.00; 95% CI, 1.03 -218.40; P ¼ .10 for dexamethasone per day). Furthermore, only patients who had received .133.5 mg dexamethasone within 28 days before RT were at risk for developing CMV-associated encephalopathy (P ¼ .005). For patients with high-grade gliomas, the risk for reactivation was increased for those who had not been eligible for resection, despite receiving the same treatment as resected patients (OR 30.56; 95% CI, 1.19-785.30; P ¼ .02). Also, the cumulative intake of ,2626 mg temozolomide per square meter of body surface was associated with an increased risk for CMV reactivation and CMV disease (OR 35.00; 95% CI, 1.74 -703.50; P ¼ .03). Status of isocitrate dehydrogenase 1 (IDH1) in tumor tissue was not a risk factor for developing CMV reactivation (P ¼ 1.00).
In the brain metastases group, dexamethasone intake within 28 days before RT was not associated with an increased risk for CMV-associated neurological decline (P ¼ 1.00). The amount of dexamethasone administered during RT, however, remained There is no statistically significant difference between the characteristics of whole group (middle column) compared with only those positive for anti-CMV IgG prior to therapy (right column).
a Plus-minus values are means+SD. Fig. 1 . The analyzed population of 50 patients who underwent WBRT for cerebral metastases or local RT for high-grade glioma was divided into group at risk for CMV encephalopathy (positive for anti-CMV IgG pretherapeutically) and group not at risk (negative for anti-CMV IgG pretherapeutically). The grey area shows the incidence of CMV viremia and CMV encephalitis for each group during RT.
Neuro-Oncology 
Outcome
There was no significant difference in overall survival between patients developing symptomatic CMV reactivation and those who were not (P ¼ .25), possibly due to only 17 patients (34%) having died at the time of analysis (Fig. 3) . At 150 days after the first day of RT, survival was 74% (14/19) (no CMV associated encephalopathy) versus 54% (7/13) (with CMV associated encephalopathy).
While the visible divergence between survival curves of patients in danger of developing CMV-associated encephalopathy (ie, all patients who showed positivity for anti-CMV IgG prior to treatment) might be suggestive of assuming lower overall survival for patients with CMV associated encephalopathy, even though all but 2 of the 13 patients, who had refused treatment, were immediately treated with (val)ganciclovir, at this point, the study is underpowered to detect a definite difference in survival.
One patient with symptomatic viremia died during RT within 2 weeks of diagnosis from bacterial pneumonia. All other patients finished RT.
Discussion
As of yet, the regular occurrence of CMV encephalitis during R(C)T of the neurocranium has been unknown, but it could potentially explain the neurological decline of some patients during RT.
Our study demonstrates that CMV-associated encephalopathy frequently (13/50; 26%) occurs in patients during brain irradiation+dexamethasone, making our results vital for the treating physicians of patients receiving RT of the brain.
Considering the fact that only patients positive for anti-CMV IgG developed the disease, this study indicates the infection to be a reactivation rather than a primary infection with an occurrence of 42% (13/32) in these patients at risk. While theoretically both RT and/or dexamethasone could be responsible for CMV reactivation, we saw that one patient naïve for dexamethasone developed CMV-associated encephalopathy.
Neurological decline is usually attributed to macroscopic or microscopic tumor progression, increased cerebral pressure, or side effects of RT. For both cerebral metastases and high-grade gliomas, it has been shown that up to 30% of patients die for unknown reasons, partially even with definite exclusion of the tumor being the cause, 18 ,19 4 months and 1 month after diagnosis, respectively. Considering the incidence of CMV-associated encephalopathy in our study collective, improvement upon antiviral treatment, and the mortality of untreated CMV encephalitis, it seems that the reactivation of CMV infection could explain some of these deaths. Due to The value "x" promoting the diversion "." and "," for dose of dexamethasone and dose of temozolomide represents the mean. a For 2 patients IDH1 status had not been determined. *P , .05; **P , .005; ***P , .001; ns: not significant.
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ethical reasons, we could not generally examine CSF of study patients with clinical and hematological diagnoses of CMV encephalopathy and therefore could not histologically prove CMV encephalitis rather than encephalopathy during CMV reactivation. One patient with diagnosed CMV encephalopathy, however, was thus examined by colleagues treating the patient after RT. They found a high-grade CMV encephalitis and had to postpone systemic therapy. CMV reactivation and secondary CMV disease of the CNS occur mainly in immunosuppressed patients (eg, transplant patients, AIDS patients). 20 Cancer patients as a collective with unspecific immunosuppression, however, showed an incidence of CMV reactivation of 9.3%. 21 Corticosteroids are known risk factors for the occurrence of CMV infection in AIDS patients 22 but also in otherwise healthy individuals. 23 Especially dexamethasone has been shown to cause CMV replication in vitro 24 and in vivo. 25 Cytomegalovirus is considered to be controlled by lymphocytes. 26, 27 While the virus inhibits the function of T cells, 21 corticosteroids are lympholytic themselves, 28 likely increasing the risk for CMV reactivation.
Radiotherapy has been shown to activate viruses in vitro 29 for example, via CMV-IE promoter. One could hypothesize that RT of tumor masses known to contain at least particles of the virus (80% -99% for high-grade gliomas 6, 30 and 92% -100% for brain metastases 9 ) can lead to local infection: encephalitis and systemic viremia. This is supported by the fact that all anti-CMV IgG positive glioblastoma patients in our study with macroscopic tumor developed CMV encephalopathy during RT. As mentioned above, however, corticosteroids are also known to be capable of CMV reactivation. As most patients with brain cancer receive corticosteroids during RT, a potential combined effect of RT and steroids in addition to their own pro-viral effect cannot be excluded. 
Our results might contribute to explain the fact that prophylactically administered valganciclovir as add-on therapy for glioblastoma patients seems to improve overall survival. 4 The authors hypothesized for this effect to be caused by antitumor effects, as demonstrated with decrease in tumor volume, while our study may suggest the effect to rather be caused by the prevention of CMV reactivation. Moreover, patients being treated with acyclovir for assumed encephalitis while actually having undiagnosed high-grade gliomas clinically improved after receiving antiviral treatment. 31 In summary, our results show that during and shortly after RT, CMV viremia occurred in 48% (13/32) of patients positive for anti-CMV IgG (32/50; 64% of patient population), 87% (13/15) of whom suffered associated clinically highly relevant encephalitis-like neurological decline (Fig. 1) .
Due to the high clinical relevance of our findings, we suggest for patients with cerebral malignancies receiving brain RT+cor-ticosteroids, to be routinely screened for anti-CMV IgG. Patients showing positivity must be closely observed and tested for CMV DNA in peripheral blood; as in our study, anti-CMV IgM was detectable in only 2 of 13 cases of CMV reactivation. Furthermore, these results support the necessity to further investigate the indication for prophylactic antiviral treatment, similar to the administration of cotrimoxazol during therapy with temozolomide.
Supplementary Material
Supplementary material is available at Neuro-Oncology Journal online (http://neuro-oncology.oxfordjournals.org/).
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